KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Working Capital Changes (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Other Working Capital Changes data on record, last reported at $15.4 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 87.78% year-over-year to $15.4 million; the TTM value through Dec 2025 reached -$11.7 million, up 42.36%, while the annual FY2025 figure was -$11.7 million, 42.36% up from the prior year.
  • Other Working Capital Changes reached $15.4 million in Q4 2025 per EBS's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $126.0 million in Q4 2024 and bottomed at -$126.8 million in Q3 2024.
  • Average Other Working Capital Changes over 5 years is -$3.3 million, with a median of $350000.0 recorded in 2023.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 1900.0% in 2021, then tumbled 25460.0% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$12.3 million in 2021, then plummeted by 59.35% to -$19.6 million in 2022, then plummeted by 53.06% to -$30.0 million in 2023, then surged by 520.0% to $126.0 million in 2024, then plummeted by 87.78% to $15.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $15.4 million in Q4 2025, $2.1 million in Q3 2025, and -$19.7 million in Q2 2025.